Media Exchange Group (CWLCD) research, news, and more from GeoInvesting

Comments & Business Outlook

Wed, 18 Apr 2012 04:00:00 GMT

Intellicell BioSciences Inc. and Subsidiary

CONSOLIDATED STATEMENTS OF OPERATIONS




	For the Year Ended			For the period from inception (August 13, 2010) to
	December 31, 2011			December 31, 2010
Revenues	$	99,192		$	164,095

Cost of goods sold		51,059			86,109

Gross margin		48,133			77,986

Operating Expenses
Research and development		222,058			229,753
Sales and marketing		507,168			32,308
General and administrative		1,510,374			270,913
Employee Stock Based Compensation		3,132,408			-
Non-Employee Stock Based Compensation		12,708,115			-

		18,080,123			532,974
Loss from operations		(18,031,990	)		(454,988	)

Other income (expense)
Interest expense		(304,038	)		-
Change in fair value of derivative liabilities		(14,502,727	)		-

		(14,806,765	)		-

Loss before income taxes		(32,838,755	)		(454,988	)

Provision for income taxes		-			-

Net loss	$	(32,838,755	)	$	(454,988	)


Loss per share:
Basic & Diluted	$	(1.77	)	$	(0.01	)

Weighted-average shares outstanding:
Basic & Diluted		18,534,764			33,577,921

Deal Flow

Mon, 12 Mar 2012 04:00:00 GMT

Between February 24, 2012 and February 29, 2012, Intellicell Biosciences, Inc. (the “Company”) entered into securities purchase agreements with accredited investors, as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company sold (i) an aggregate of 435,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) class A warrants to purchase an aggregate of 870,000 shares of Common Stock (the “Class A Warrants”), and (iii) class B warrants to purchase an aggregate of 870,000 shares of Common Stock (the “Class B Warrants” and together with the Class A Warrants, the “Warrants”), for aggregate gross cash proceeds of $435,000. To date, the Company has sold its Common Stock and Warrants for aggregate gross proceeds of $2,475,000, which consisted of $1,975,000 of cash and the exchange and cancelation of a promissory note (bearing principal and interest totaling $500,000) and a warrant.

Deal Flow

Fri, 24 Feb 2012 05:00:00 GMT

February 2012 Private Placement

In February 2012, Intellicell Biosciences, Inc. (the “Company”) entered into securities purchase agreements with accredited investors, as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company sold (i) an aggregate of 2,040,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) class A warrants to purchase an aggregate of 4,080,000 shares of Common Stock (the “Class A Warrants”), and (iii) class B warrants to purchase an aggregate of 4,080,000 shares of Common Stock (the “Class B Warrants” and together with the Class A Warrants, the “Warrants”), for aggregate gross proceeds of $2,040,000, which consisted of $1,540,000 of cash and the exchange and cancelation of a promissory note (bearing principal and interest totaling $500,000) and a warrant.

Deal Flow

Mon, 06 Feb 2012 05:00:00 GMT

On January 27, 2012, Intellicell Biosciences, Inc. (the “Company”) entered into a securities purchase agreement with an accredited investor, as defined in Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company sold an aggregate of twelve thousand five hundred (12,500) shares of our series D convertible preferred stock and a warrant to purchase one hundred twenty-five thousand shares (125,000) of the Company’s common stock, for aggregate gross proceeds of $250,000. On December 15, 2011, this same investor had purchased the same number of shares (12,500) of our series D preferred stock and warrants to purchase the same number of shares of common stock (125,000) on the same terms and conditions as set forth above, for aggregate gross proceeds of $250,000.